- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Glenmark Pharmaceuticals Limited — Updates, 24-09-2025: Press Release
24-09-2025 | 03:39 pm
24-09-2025 | 03:39 pm
Glenmark's subsidiary partners with Hengrui for exclusive rights to their HER2-targeting ADC, Trastuzumab Rezetecan, across key regions. The deal involves an US$18 million upfront payment, potential milestones up to US$1.093 billion, and royalties, boosting Glenmark's oncology pipeline.
No comments yet. Be the first to comment!